The goal of the Abramson Cancer Center (ACC) of the University of Pennsylvania is to bring together more than 310 members to transform the paradigm of patient-centered cancer care and cancer control by integrating high impact Programs of basic, clinical, and population-based research, fostering pioneering scientific discoveries, and facilitating the translation of these discoveries into clinical practice. In doing so, the ACC builds upon the great clinical cancer care at renowned hospitals of the University of Pennsylvania and the Children?s Hospital of the Philadelphia. The ACC continues to build on its significant historical strengths in basic cancer biology, translational immunotherapy, and population science research. By leveraging the infusion of new Institutional resources and significant philanthropic resources, the ACC will continue to innovate to reduce the burden of cancer in our catchment area during the next project period and will seek to: (1) Accelerate and expand its leadership in adoptive cellular immunotherapy, combination immune checkpoint therapies, and vaccine development for both prevention and treatment of cancers. (2) Increase translation of cancer basic biology through the philanthropic and Institutionally supported ACC Translational Centers of Excellence that integrate basic, translational and clinical scientists from the ACC Programs to impact on the prevention, detection, and treatment of specific types of cancers that afflict our catchment area. (3) Accelerate precision cancer medicine through novel Molecular Imaging, the Center for Personalized Diagnostics, the Molecular Tumor Board, and the Circulating Tumor Material Developing Core, which were implemented in the past project period, and the implementation of the Center for Rare Cancers and Personalized Therapy in the next project period. (4) Innovate means to understand, prevent, and treat therapy-resistant cancers by incorporating genomics, epigenomics, informatics and research in cancer metabolism, which is frequently re-wired in resistance to targeted therapies. (5) Lead population-based research through recruitment and research tools in genetics and complex traits with an emphasis on cancer epidemiology. Implement projects in cancer molecular epidemiology among patients of African descent and accelerate our Outreach Program to increase research relevant to our catchment area. (6) Launch a new Brain and Behavior Change initiative and harness new tools from cognitive neurosciences to control cancer by modulating behaviors that predispose to smoking or contribute to obesity. Lead in Toxicology and Environmental Carcinogenesis to understand environmental toxins and impact the health of patients with mesothelioma in our catchment area.

Public Health Relevance

Cancer is the second leading cause of the death in the United States and is prevalent in our ethnically diverse catchment area, which consists of 15 contiguous counties of the Greater Delaware Valley covering the States of Pennsylvania, New Jersey, and Delaware, from which 87% of all ACC's patients originate. Through our research initiatives, our Programs are positioned to address the burden imposed by highly prevalent cancers in the catchment area, including breast, lung, and gastrointestinal cancers. Basic, clinical, and population science research in the ACC are integrated to prevent, diagnose, and treat these cancers not only in our catchment area, but also well beyond this boundary. In addition, our Program in Melanoma and Cutaneous Malignancies actively engages the community through education and outreach to reduce sun exposure and impact legislation to restrict access to tanning salons.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Han, Joseph; Lachance, Catherine; Ricketts, M Daniel et al. (2018) The scaffolding protein JADE1 physically links the acetyltransferase subunit HBO1 with its histone H3-H4 substrate. J Biol Chem 293:4498-4509
Waxman, Adam J; Clasen, Suparna; Hwang, Wei-Ting et al. (2018) Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4:e174519
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Reshef, Ran; Ganetsky, Alex; Acosta, Edward P et al. (2018) Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biol Blood Marrow Transplant :
Lang, Fengchao; Sun, Zhiguo; Pei, Yonggang et al. (2018) Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy. PLoS Pathog 14:e1007253
Rosenfeld, Aaron M; Meng, Wenzhao; Luning Prak, Eline T et al. (2018) ImmuneDB, a Novel Tool for the Analysis, Storage, and Dissemination of Immune Repertoire Sequencing Data. Front Immunol 9:2107
Kushner, Carolyn J; Hwang, Wei-Ting; Wang, Shiyu et al. (2018) Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Res Treat 170:45-53
Buljan, Vlado A; Graeber, Manuel B; Holsinger, R M Damian et al. (2018) Calcium-axonemal microtubuli interactions underlie mechanism(s) of primary cilia morphological changes. J Biol Phys 44:53-80
Min, Eun Jeong; Safo, Sandra E; Long, Qi (2018) Penalized Co-Inertia Analysis with Applications to -Omics Data. Bioinformatics :
Chang, Changgee; Kundu, Suprateek; Long, Qi (2018) Scalable Bayesian variable selection for structured high-dimensional data. Biometrics :

Showing the most recent 10 out of 1047 publications